Syncona Shs GBP (SYNC) Price & Analysis

Q: What was Syncona Shs GBP ’s price range in the past 12 months?

Syncona Shs GBP lowest share price was 77.32p and its highest was 102.60p in the past 12 months.

Q: When is Syncona Shs GBP ’s upcoming earnings report date?

Syncona Shs GBP ’s upcoming earnings report date is Jun 11, 2026 which is in 102 days.

Q: How were Syncona Shs GBP ’s earnings last quarter?

Syncona Shs GBP released its earnings results on Nov 13, 2025. The company reported -0.042p earnings per share for the quarter, missing the consensus estimate of N/A by -0.042p.

Q: Is Syncona Shs GBP overvalued?

According to Wall Street analysts Syncona Shs GBP ’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Syncona Shs GBP pay dividends?

Syncona Shs GBP pays a Annually dividend of 2.3p which represents an annual dividend yield of N/A. See more information on Syncona Shs GBP dividends here

Q: What is Syncona Shs GBP ’s EPS estimate?

Syncona Shs GBP ’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Syncona Shs GBP have?

Syncona Shs GBP has 608,193,050 shares outstanding.

Q: What happened to Syncona Shs GBP ’s price movement after its last earnings report?

Syncona Shs GBP reported an EPS of -0.042p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.599%.

Q: Which hedge fund is a major shareholder of Syncona Shs GBP ?

Currently, no hedge funds are holding shares in GB:SYNC

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

19 Followers

SYNC Stock Chart & Stats

93.90p

1.15p(1.28%)

At close: Jan 09 4:00 PM EST

93.90p

1.15p(1.28%)

Day’s Range― - ―

52-Week Range77.32p - 102.60p

Previous CloseN/A

Volume94.05K

Average Volume (3M)483.92K

Market Cap

N/A

Enterprise Value584.87M

Total Cash (Recent Filing)£213.00K

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta0.47

Next Earnings

Jun 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding608,193,050

10 Day Avg. Volume510,558

30 Day Avg. Volume483,919

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.51

Price to Sales (P/S)-7.82

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetA strong balance sheet with zero debt enhances financial stability and provides flexibility for future investments and growth opportunities.

Improved Cash FlowImproved cash flow indicates efficient cash management, supporting operational needs and strategic investments, enhancing long-term sustainability.

Strategic Share BuybackThe share buyback program reflects strategic capital management, potentially enhancing shareholder value and signaling confidence in the company's prospects.

Bears Say

Revenue VolatilityRevenue volatility poses challenges for consistent profitability, impacting long-term financial planning and investor confidence.

Negative Valuation MetricsNegative valuation metrics suggest potential overvaluation concerns, which could affect investor sentiment and capital raising capabilities.

Market ChallengesBearish market trends indicate potential challenges in stock performance, affecting investor confidence and market positioning.

Syncona Shs GBP News

Syncona Refines Investment Strategy and Incentives Ahead of Shareholder Vote

Syncona Shs GBP ( ($GB:SYNC) ) has issued an announcement. Syncona Limited has published a circular detailing a...

17d ago

Syncona Posts Strong Q3 NAV Gains as Beacon Financing and Late‑Stage Pipeline Drive Outlook

The latest update is out from Syncona Shs GBP ( ($GB:SYNC) ). Syncona reported a solid third quarter,...

24d ago

Syncona Ups Beacon Therapeutics Stake as Gene Therapy Group Raises $75m Series C

Syncona Shs GBP ( ($GB:SYNC) ) has shared an update. Syncona has committed $24.5 million to Beacon Therapeutics’...

2M ago

Syncona Limited Announces Total Voting Rights Update

Syncona Shs GBP ( ($GB:SYNC) ) just unveiled an announcement. Syncona Limited has announced that as of 28...

3M ago

Syncona Limited to Issue New Shares Under Incentive Scheme

Syncona Shs GBP ( ($GB:SYNC) ) has issued an announcement. Syncona Limited announced the issuance of 334,788 new...

3M ago

Syncona Limited Reports Interim Results, Positions for Growth in Biotech Sector

An update from Syncona Shs GBP ( ($GB:SYNC) ) is now available. Syncona Limited announced its interim results...

4M ago

Syncona Highlights Autolus Therapeutics’ Q3 2025 Financial Performance and Strategic Growth

The latest announcement is out from Syncona Shs GBP ( ($GB:SYNC) ). Syncona Limited, a prominent life science...

4M ago

Syncona Unveils Strategic Update to Maximize Shareholder Value

The latest announcement is out from Syncona Shs GBP ( ($GB:SYNC) ). Syncona Limited has announced a strategic...

4M ago

Beacon Therapeutics’ Gene Therapy Shows Promise in Phase 2 Trials for XLRP

Syncona Shs GBP ( ($GB:SYNC) ) has shared an update. Syncona Limited, a prominent life science investor, highlights...

6M ago

Autolus Therapeutics Reports Q2 2025 Results and Advances Clinical Trials

Syncona Shs GBP ( ($GB:SYNC) ) has provided an announcement. Autolus Therapeutics, a portfolio company of Syncona Limited,...

7M ago

SYNC FAQ

What was Syncona Shs GBP ’s price range in the past 12 months?

Syncona Shs GBP lowest share price was 77.32p and its highest was 102.60p in the past 12 months.

What is Syncona Shs GBP ’s market cap?

Currently, no data Available

When is Syncona Shs GBP ’s upcoming earnings report date?

Syncona Shs GBP ’s upcoming earnings report date is Jun 11, 2026 which is in 102 days.

How were Syncona Shs GBP ’s earnings last quarter?

Syncona Shs GBP released its earnings results on Nov 13, 2025. The company reported -0.042p earnings per share for the quarter, missing the consensus estimate of N/A by -0.042p.

Is Syncona Shs GBP overvalued?

According to Wall Street analysts Syncona Shs GBP ’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Syncona Shs GBP pay dividends?

Syncona Shs GBP pays a Annually dividend of 2.3p which represents an annual dividend yield of N/A. See more information on Syncona Shs GBP dividends here

What is Syncona Shs GBP ’s EPS estimate?

Syncona Shs GBP ’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Syncona Shs GBP have?

Syncona Shs GBP has 608,193,050 shares outstanding.

What happened to Syncona Shs GBP ’s price movement after its last earnings report?

Syncona Shs GBP reported an EPS of -0.042p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.599%.

Which hedge fund is a major shareholder of Syncona Shs GBP ?

Currently, no hedge funds are holding shares in GB:SYNC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Syncona Shs GBP

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.